Department of Anesthesiology and Pain Medicine, University of California Davis, Sacramento, CA, USA.
Department of Anesthesiology and Pain Medicine, University of California Davis, Sacramento, CA, USA.
Neuromodulation. 2024 Jul;27(5):805-811. doi: 10.1016/j.neurom.2023.12.003. Epub 2024 Feb 7.
Neuromodulation represents one of the more advanced tools in the armamentarium of pain physicians. To optimize neuromodulation patient selection and management, an institutional interdisciplinary neuromodulation committee was created at each of two academic medical centers (University of California Davis [UCD] and Stanford University). The committee aims to collaboratively optimize neuromodulation candidates, to assess and minimize medical and psychologic risks, and to select the best device given a patient's pain condition. In this study, we present the methods and outcome data of the Neuromodulation Committee at the two institutions.
After institutional review board approval, we included all adult patients who were evaluated by the Neuromodulation Committee between 2017 and 2020 at two academic pain clinics. Patients with insufficient data were excluded from the study. A retrospective chart review was completed on 385 UCD and Stanford University patient committee reviews. Data collected from the chart review included demographics (age, sex), committee meeting results (proceed with trial/implant or decline), trial success, and implant rate.
Of the 385 patients screened, the committees recommended proceeding with an implantable device (peripheral and neuraxial) in 337 patients (87.5%). Of the 278 patients recommended for neuraxial neuromodulation, 131 underwent trials with percutaneous leads (47.1%). Trials were successful (causing a ≥50% reduction in self-reported pain or improved function) in 108 patients (82.4%). The institutions completed 87 implants of 131 trials, representing a trial-to-permanent ratio of 66.4%.
The Neuromodulation Committee aims to identify optimal patients for neuromodulation, address procedural challenges, decrease adverse events, provide educational context for trainees, and improve patient-related outcomes. Patients who were recommended for neuromodulation and subsequently underwent intervention had high trial success rates for dorsal root ganglion stimulation and spinal cord stimulation. The findings indicate that such an approach can lead to neuromodulation success, especially at academic centers, by combining the expertise of both medical and psychologic professionals.
神经调节是疼痛医师治疗手段中较为先进的方法之一。为了优化神经调节患者的选择和管理,两所学术医疗中心(加利福尼亚大学戴维斯分校[UCD]和斯坦福大学)均成立了机构间神经调节委员会。该委员会旨在共同优化神经调节候选人,评估和最小化医疗和心理风险,并根据患者的疼痛状况选择最佳设备。在这项研究中,我们介绍了这两个机构的神经调节委员会的方法和结果数据。
在机构审查委员会批准后,我们纳入了 2017 年至 2020 年间在两所学术疼痛诊所接受神经调节委员会评估的所有成年患者。研究排除了数据不足的患者。对 385 例 UCD 和斯坦福大学患者委员会审查的病历进行了回顾性分析。从病历回顾中收集的数据包括人口统计学资料(年龄、性别)、委员会会议结果(进行试验/植入或拒绝)、试验成功率和植入率。
在筛选出的 385 例患者中,委员会建议对 337 例(87.5%)患者植入可植入设备(外周和神经轴)。在建议进行神经轴神经调节的 278 例患者中,有 131 例接受了经皮导联试验(47.1%)。在 108 例(82.4%)患者中,试验成功(导致自我报告疼痛减轻≥50%或功能改善)。这两个机构完成了 131 次试验中的 87 次植入,试验到永久植入的比例为 66.4%。
神经调节委员会旨在确定最佳的神经调节患者,解决程序挑战,减少不良事件,为学员提供教育背景,并改善患者相关结局。被推荐进行神经调节且随后接受干预的患者,背根神经节刺激和脊髓刺激的试验成功率很高。这些发现表明,通过结合医学和心理专业人员的专业知识,这种方法可以在学术中心实现神经调节的成功。